Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E56.80 EPS (ttm)0.49 Insider Own0.90% Shs Outstand294.38M Perf Week-6.91%
Market Cap8.24B Forward P/E36.08 EPS next Y0.78 Insider Trans-25.63% Shs Float285.66M Perf Month7.40%
Income150.90M PEG1.23 EPS next Q0.12 Inst Own82.80% Short Float5.90% Perf Quarter1.71%
Sales410.00M P/S20.10 EPS this Y63.70% Inst Trans-0.09% Short Ratio5.98 Perf Half Y3.74%
Book/sh0.81 P/B34.57 EPS next Y57.09% ROA26.10% Target Price33.71 Perf Year56.42%
Cash/sh1.25 P/C22.45 EPS next 5Y46.00% ROE101.20% 52W Range16.72 - 32.50 Perf YTD-7.89%
Dividend- P/FCF43.54 EPS past 5Y-19.90% ROI-15.10% 52W High-10.80% Beta1.81
Dividend %- Quick Ratio4.30 Sales past 5Y-7.90% Gross Margin96.90% 52W Low73.39% ATR1.18
Employees287 Current Ratio4.30 Sales Q/Q145.20% Oper. Margin39.30% RSI (14)50.97 Volatility5.84% 4.20%
OptionableYes Debt/Eq0.00 EPS Q/Q690.80% Profit Margin36.80% Rel Volume1.19 Prev Close28.00
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 AMC Payout0.00% Avg Volume2.82M Price28.99
Recom2.30 SMA20-2.92% SMA504.47% SMA20015.21% Volume1,842,961 Change3.54%
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks
Jan-20-18 10:55AM  Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Business Wire
Jan-19-18 10:59AM  Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year Zacks
10:23AM  Cancer Space Update: Label Expansions, Data Readouts in Focus Zacks
08:46AM  BeiGene (BGNE) Surges: Stock Moves 12.6% Higher Zacks
Jan-18-18 10:04AM  BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa Zacks
Jan-17-18 04:19PM  Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results Investor's Business Daily -7.28%
10:48AM  Merck Strong on Confirmatory Phase III Lung Cancer Study Zacks
09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
08:06AM  Exelixis, Ipsen Report Positive Results on Lead Cancer Drug Zacks
Jan-16-18 05:33PM  Exelixis, Ipsen report positive cancer-study results MarketWatch
05:01PM  Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma Business Wire
10:45AM  Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins? Market Realist
10:12AM  Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018? Zacks
09:15AM  Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance Market Realist
08:35AM  Novartis (NVS) Announces Acceptance of Humira BLA by the FDA Zacks
07:40AM  Analyst Recommendations for Vertex Pharmaceuticals in January Market Realist
Jan-15-18 08:24AM  Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion Zacks
07:37AM  Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead? Zacks
06:53AM  Roche MS Drug Ocrevus Gets Marketing Authorization in Europe Zacks
Jan-12-18 12:46PM  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote Zacks
10:05AM  Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock? Zacks
09:16AM  The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex Zacks
09:05AM  Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod Zacks
08:04AM  Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse Zacks
Jan-11-18 10:19AM  Can Biotech Keep Last Year's Momentum Alive in 2018? Zacks
09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
12:02AM  How Do Analysts See Exelixis Inc (NASDAQ:EXEL) Performing Over The Next Few Years? Simply Wall St.
Jan-10-18 10:33AM  4 Reasons Exelixis, Inc. More Than Doubled in 2017 Motley Fool
09:00AM  Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home Zacks
09:00AM  Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up Zacks
Jan-09-18 05:04PM  Emergent Down on '18 View, Posts Preliminary '17 Results Zacks
04:35PM  Acorda's Shares Down on Disappointing Ampyra View for 2018 Zacks
09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
08:48AM  Agenus Inc., (AGEN) Jumps: Stock Rises 11.4% Zacks
08:00AM  Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Business Wire
Jan-08-18 03:42PM  Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma Zacks -7.34%
08:54AM  Alnylam, Sanofi Announce Restructuring Deal for RNAi Products Zacks
08:49AM  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines Zacks
08:00AM  Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies Business Wire
Jan-05-18 07:20PM  Top 5 Biotech Stocks for 2018 Investopedia
04:25PM  4 Biotech Stocks to Watch in the New Year Zacks
01:43PM  Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial Zacks
09:47AM  Emergent Starts Phase II Study on Anti-influenza Candidate Zacks
Jan-04-18 02:21PM  The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December Motley Fool
09:58AM  United Therapeutics (UTHR) Collaborates With Corsair Pharma Zacks
09:53AM  Pfizer (PFE) Collaborates With Sangamo for Gene Therapy Zacks
08:00AM  Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors Business Wire
Jan-03-18 09:41AM  Inovio Amends Chinese Deal for Immunotherapy, Shares Up Zacks
05:40AM  Valeant (VRX) to Settle Allergan Litigation for $290 Million Zacks
Jan-02-18 08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Dec-28-17 08:39AM  Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018? Zacks
Dec-26-17 11:29AM  ETFs with exposure to Exelixis, Inc. : December 26, 2017 Capital Cube
03:00AM  Stocks Showing Market Leadership: Exelixis Earns 93 RS Rating Investor's Business Daily
Dec-22-17 10:07AM  Cancer Space Update: FDA Approves Label Expansion of 4 Drugs Zacks +5.97%
Dec-21-17 09:17AM  Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors Motley Fool
08:52AM  What's Happening in Advanced Renal Cell Carcinoma Space? Zacks
Dec-20-17 02:00PM  Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer Motley Fool +5.02%
01:45PM  Exelixis Wins Big With FDA Approval 24/7 Wall St.
09:01AM  Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer Zacks
06:30AM  Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy Zacks
03:00AM  Stocks Showing Improving Market Leadership: Exelixis Earns 83 RS Rating Investor's Business Daily
Dec-19-17 04:50PM  Pfizer, Exelixis cancer drugs get FDA approval for wider use Reuters
03:33PM  Exelixis, Inc.s (EXEL) RCC Treatment Gets Early FDA Approval SmarterAnalyst
02:54PM  Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma Business Wire
Dec-15-17 08:02AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 15, 2017 Capital Cube
Dec-12-17 11:12AM  Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run InvestorPlace
09:31AM  3 Top Healthcare Stocks to Buy in December Motley Fool
Dec-08-17 08:04AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Dec-07-17 09:11AM  Is Exelixis, Inc. a Buy? Motley Fool
Dec-04-17 01:45PM  Analysts Recommendations for Regeneron Market Realist
Dec-01-17 03:00AM  Stocks To Watch: Exelixis Sees Relative Strength Rating Rise To 84 Investor's Business Daily
Nov-30-17 08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-27-17 08:15AM  Report: Developing Opportunities within PayPal, Exelixis, International Business Machines, Opko Health, Envision Healthcare, and Zynga Future Expectations, Projections Moving into 2018 GlobeNewswire
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
07:50AM  Blog Exposure - Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma ACCESSWIRE
Nov-25-17 11:02AM  Best Growth Stocks To Buy Simply Wall St.
Nov-23-17 07:31AM  Gauging Exelixiss High Hopes for Cotellic Market Realist
Nov-22-17 10:32AM  Inside Exelixiss Label Expansion Collaborations for Cabozantinib Market Realist
09:03AM  What Else Could Boost Exelixiss Future Revenues? Market Realist
07:33AM  Behind Exelixiss Cabometyx Strategy for 2018 Market Realist
Nov-21-17 04:45PM  Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations Business Wire
04:30PM  Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium Business Wire
02:55PM  Reading the Expectations for Exelixiss Net Profit Margin in 2017 Market Realist
01:25PM  Whats Really Driving Exelixiss 2017 Revenues? Market Realist
11:54AM  Exelixis and Peers in November: Analyst Recommendations Market Realist
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
08:00AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 21, 2017 Capital Cube
Nov-20-17 12:23PM  ETFs with exposure to Exelixis, Inc. : November 20, 2017 Capital Cube
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-17-17 08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-16-17 09:41AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-15-17 08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-12-17 09:09AM  Better Buy: Exelixis, Inc. vs. Novartis AG Motley Fool
Nov-10-17 08:08AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
07:59AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 10, 2017 Capital Cube
Nov-09-17 12:40PM  ETFs with exposure to Exelixis, Inc. : November 9, 2017 Capital Cube
12:39PM  Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up Zacks
09:45AM  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Zacks
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garber Alan MDirectorJan 09Option Exercise7.9711,50091,65572,829Jan 10 07:27 PM
Garber Alan MDirectorJan 09Sale30.0011,500345,00061,329Jan 10 07:27 PM
Garber Alan MDirectorJan 08Option Exercise7.973,50027,89564,829Jan 10 07:27 PM
Garber Alan MDirectorJan 08Sale31.293,500109,51561,329Jan 10 07:27 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Option Exercise9.9133,334330,340216,339Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 28Option Exercise1.9025,00047,500292,946Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 28Sale24.3225,000608,000267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Sale23.7433,334791,349183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Option Exercise1.902,3024,374270,248Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 27Sale23.902,30255,018267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Sale23.9433,333797,992183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Sale23.6833,333789,325183,005Sep 28 07:45 PM
PAPADOPOULOS STELIOSDirectorSep 22Sale25.4010,000254,0000Sep 22 07:07 PM
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM